NCT01478126

Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass

Prospective Randomized Study of Glutamin Protective Properties in Cardiac Surgery.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Meshalkin Research Institute of Pathology of Circulation · Network
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether perioperative glutamine administration possess protective properties on internal organs (heart and gut) in patients with coronary atherosclerosis, operated under cardiopulmonary bypass.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	N(2)-L-Alanine L-Glutamine dipeptide	Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2\*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
DRUG	Placebo	Intravenous infusion of 0,9% solution of NaCl, rate=2\*weight/24. Infusion starts in operating room and ends next day after the surgery.

Timeline

• Start date: 2012-01-01
• Primary completion: 2012-12-01
• Completion: 2013-09-01
• First posted: 2011-11-23
• Last updated: 2013-11-01

Locations

1 site across 1 country: Russia